loncastuximab tesirine-lpyl (Zynlonta)

Indications

• treatment of diffuse large B-cell lymphoma

Contraindications

• pregnancy

Dosage

• 0.15 mg/kg every 3 weeks for 2 cycles
• 0.075 mg/kg every 3 weeks for subsequent cycles
• dexamethasone 4 mg PO or IV BID for 3 days beginning the day before administering Zynlonta

* 10 mg as lyophilized powder for reconstitution & further dilution

* reconstitute in 2.2 mL of Sterile Water for Injection, USP with the stream directed toward the inside wall of the vial to obtain a final concentration of 5 mg/mL

* store reconstituted solution in the vial for up to 4 hours refrigerated or at room temperature; do not freeze

Adverse effects

• >= 20%
• fatigue, nausea, musculoskeletal pain
• laboratory
  • thrombocytopenia, increased serum GGT, neutropenia, anemia, hyperglycemia, serum transaminase elevation, hypoalbuminemia
• effusion & edema
  • pleural effusion, pericardial effusion, ascites, peripheral edema
• myelosuppressioon
• infections
• cutaneous reactions: photosensitivity
• fetus, embryo harm

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• CD19-directed antibody & alkylating agent conjugate

More general terms

• antineoplastic monoclonal antibody